参考文献

[1]Li Ying-hua,Geng Jian-lin,Li Wen-xiao,et al.Clinical Analysis of the elderly patient with Acguired Hemophilia A[J].Chinese Journal of Thrombosis and Hemostasis,2010, 16(1):30-32.

[2]叶应妩,王毓三,申子瑜.全国临床检验操作规程[M].南京:东南大学出版社,2009:212-223.

[3]王振义,李家增,阮长耿, 等.血栓与止血基础理论与临床[M].3版.上海:上海科学技术出版社,2004:397-416.

[4]Yan Zhen-yu.Development of factorⅧ Inhibitor in the patients with Hemophilia A:risk Factors and pathogenesis[J].Chinese Journal of Thrombosis and Hemostasis,2010, 15(4):108-182.

[5]Wagenman B,Townsend K,Mathew P,et al.The laboratory approach to inherited and acguired coagulation Factor deficiencies[J].Clin Lab Med,2009,29(2):229-252.

[6]Ghosh K, Shetty S.Immune response to FⅧHemophiliaA:an overview of risk factors[J].Clin Rev All-ergy Immunol,2009,37:58 -66.(https://www.daowen.com)

[7]Huthkuhne A, Baudo F, Collins P, et al.International recommendations on the diagnosis and treatment of patients with acguired hemophilia A[J].Haematologica, 2009,94(4):566-575.

[8]Amano K.Notes on laboratory coagulation testing for acguired Hemophilia A[J].Rinsho Byori, 2009, 57(10):999-1003.

[9]Peerlinck K,Hermans C.Epidemiology of inhibitor formation with recombinant factorⅧ replace-ment therapy[J].Haemophilia, 2006, 12: 579-590.

[10]Gouw S C,Vanden Berg H M.The multifactorial etiology of inhibitor development in hemophilia: genetics and environment[J].Semin Thromb Hemost, 2009, 35:723-734.

[11]Wang X F, Zhao Y Q,Yang R C, et al.The prevalence of factorⅧ inhibitors and genetic aspects of inhibitor development in Chinese patients with hemophilia A[J].Haemophilia,2010,16:632-639.

[12]Ghosh K,Shetty S.Immune response to FⅧ in hemophilia overview of risk factors[J].Clin Rev Allergy Immunol, 2009,137:58-66.